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Formation of true new blood vessels, or angiogenesis,
and development of collateral vessels from preexisting
blood vessels, or arteriogenesis, are important in the patho-
physiology of vascular disease. By stimulating these pro-
cesses we might be able to provide an alternative treatment
strategy for patients with lower limb ischemia and coronary
artery disease.
Use of therapeutic angiogenesis, eg, stimulating angio-
gensis to treat ischemia in the heart or leg, was begun
almost a decade ago. Since then a number of studies have
reported improved restoration of perfusion as a result of
angiogenesis in animal models of limb ischemia after ad-
ministration of vascular growth factors or after overexpres-
sion with gene therapy. Therapeutic angiogenesis has also
been tried in patients. Trials showing beneficial effects of
treatment with recombinant vascular growth factors in
nonrandomized patient series are common, whereas data
from controlled clinical trials in patients with limb ischemia
are scarce. More trial data are available for coronary artery
disease, but the results are not consistent, showing both no
effect compared with placebo, as well as slight improve-
ment of heart perfusion and function.
After the initial enthusiasm for therapeutic angiogene-
sis, lack of positive trial data has reduced the optimism
somewhat. Negative study results have focused researchers
and clinicians on the fact that the angiogenesis and arterio-
genesis processes are complex and that simply supplying
vascular growth factor to the leg is usually not sufficient for
effective therapy. Therefore more interest and research
efforts are now devoted to understanding the basic mech-
anisms of these processes. This review discusses the basic
mechanisms underlying angiogenesis and arteriogenesis,
and provides speculation as to how this knowledge influ-
ences our view of the pathophysiology and treatment of
lower limb ischemia.
BASIC MECHANISMS OF ANGIOGENESIS
Angiogenesis is a physiologic process required for the
menstrual cycle and wound healing in adults. It also has a
role in pathologic processes, eg, tumor growth, rheumatoid
arthritis, diabetes, and cardiovascular disease. The angio-
genic process is complex and not yet fully understood, but
a number of growth-promoting factors regulate induction
of angiogenesis (Table). Most stimulate proliferation and
migration of cells in the vascular wall and inhibit apoptosis.
The angiogenic process originates from preexisting
capillaries in the vicinity of the ischemic insult (Fig 1). The
initial step is stimulation of endothelial cells by vascular
growth factors. The vascular endothelial cell growth factor
(VEGF) family of proteins is probably the most important
for angiogenesis, but this has recently been questioned.1
An ischemic environment in the tissue induces VEGF syn-
thesis in many different cell types. Hypoxia is one of the
stronger inducers, which act by binding hypoxia-inducible
factor-1 (HIF-1) to the hypoxia response area in the
VEGF gene promoter region. VEGF transcription is also
induced by hypoglycemia and acidosis and is further stim-
ulated by other growth factors, eg, platelet-derived growth
factor and fibroblast growth factor-2 (FGF-2).2 The VEGF
family consists of six members, where VEGF-A is the first
identified (also called simply VEGF). Splicing of the
VEGF-A gene results in five isoforms of VEGF-A, differing
in total amino acid number. It is probable that these
isoforms have different functions in the angiogenic process.
For example, VEGF-A189 may exclusively stimulate endo-
thelial cell proliferation, whereas VEGF-A165, the pre-
dominant form, also stimulates endothelial cells to coalesce
and form larger vessels.
The next step in the angiogenic process is a VEGF-
mediated increase in vascular permeability. This is due to
alterations in cell membrane structure and redistribution of
intracellular adhesion molecules PECAM-1 and vascular
endothelial-cadherin. Vascular permeability is controlled
and downregulated by angiopoetin-1. Extravasation of
plasma proteins, stimulated by VEGF, follows, creating an
environment to support endothelial cell migration. Degra-
dation of extracellular matrix, by angiopoetin-2 and a num-
ber of proteinases, mostly matrix metalloproteinases
(MMP), is also a part of this preparation.
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Endothelial cell proliferation and migration, two im-
portant effects of VEGF, are mediated through three cell
surface VEGF receptors. VEGFR-2 (KDR/Flk-1) mediates
most of the mitogenic, survival, and permeability effects of
VEGF and is mainly expressed on endothelial cells.
VEGFR-1 (Flt-1) is expressed on inflammatory cells, and
VEGFR-3 is found in lymphatic endothelium. There are
also a number of co-receptors, eg, neurophilins, proteogly-
Table 1. Examples of cytokines believed to be involved in angiogenesis and arteriogenesis
Growth factor
Cellular function
Upregulates
expression or
function
Effect on
angiogenesis/arteriogenesis
EC
proliferation
SMC
proliferation
Matrix
production
VEGF   0 eNOS,
MCP-1
/
FGF-2 (bFGF)   0 VEGF,
eNOS,
MCP-1,
HGF
(?)/
PDGF (?)  0 TGF-beta,
FGF-2,
VEGF
0/
TGF-beta  and   and   PDGF,
FGF-2,
VEGF
/
Angiopoetin-1  0 (?) /0(?)
Angiopoetin-2  and    /
MCP-1  (?) 0 0/
GM-CSF IL-8 0/
TNF-alfa  and  0(?) VEGF (?) /
HGF FGF-2 /(?)
Placental growth factor () VEGF /
EC, Endothelial cell; SMC, smooth muscle cell; VEGF, vascular endothelial cell growth factor; FGF, fibroblast growth factor; PDGF, platelet-device growth
factor; TGF, transforming growth factor; MCP, monocyte chemoattractant protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF, tumor
necrosis factor; eNOS, endothelial nitric acid synthase; HGF, hepatocyte growth factor; IL, interleukin; , stimulatory;  inhibitory; 0, no effect; ?, unclear.
Fig 1. Schema of possible events in the angiogenic process. EC, Endothelial cell.
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cans, cadherins, and integrins. VEGF receptor signal trans-
duction is not entirely clear. For example, the purpose of
VEGFR-1 binding may be only as a negative regulator of
VEGFR-2. In common with the VEGF protein, receptor
expression is upregulated by hypoxia.
When the endothelial cells reach the extracellular ma-
trix, they form cords and subsequently a lumen. This is
accomplished by thinning of the endothelial cells and fu-
sion with existing vessels. Various VEGF isoforms, angio-
poetins, and integrins regulate lumen diameter. Transform-
ing growth factor– and platelet-derived growth factor
stimulate extracellular matrix production and recruit peri-
cytes to stabilize the new vessel structure.
BASIC MECHANISMS OF ARTERIOGENESIS
Arteriogenesis, when the lumen of preexisting vessels
increases to form collateral arteries, is a process that can
ameliorate the harmful effects of vessel obstruction. Usually
arterioles become large conductance vessels that maintain
blood flow after myocardial infarction or limb ischemia.
Not all vessels can become collateral vessels, and there is a
large difference in this capacity between species, vascular
beds, and probably also individuals.
Once stenosis in a large main artery becomes hemody-
namically significant, blood flow is directed toward the
lowest resistance into the periphery via preexisting arte-
rioles (Fig 2). The initial step in the arteriogenesis process is
elevation of shear stress against the wall of these arterioles.
Shear stress can be considered frictional wall pressure at the
cell surface, caused by blood flow and the compensatory
forces striving to counteract this pressure. It is not known
how endothelial cells become activated in response to in-
creased shear stress. There may be specific shear stress
receptors on the cell surface, and multiple intracellular
signaling pathways probably mediate shear stress regulation
of gene expression.3 The latter converge to activate tran-
scription factors, shear stress response elements. Candi-
dates for shear stress receptors are caveole, integrins, and
tyrosine kinase receptors (one is VEGFR-1).
Endothelial cells react by activating endothelial nitric
oxide synthetase and genes for cytokines (probably through
shear stress response elements). the most important being
monocyte chemoattractant protein-1 (MCP-1), granulo-
cyte-macrophage colony-stimulating factor (GM-CSF), tu-
mor necrosis factor-, and cell adhesion molecules.4 At-
tracted by MCP-1 and aided by adhesion molecules,
circulating monocytes adhere to and invade the vascular
wall. Platelets also adhere and produce interleukin-4, fur-
ther stimulating adhesion molecule synthesis. The main
role of GM-CSF is to provide an environment for stable
monocyte function. Accordingly, this stage can be regarded
as local inflammation in the vessel wall.
After transformation to macrophages, monocytes pro-
duce fibronectin, proteoglycans, and proteases, which re-
model the extracellular matrix. These inflammatory cells
also produce large amounts of vascular growth factors
(Table), essentially from the FGF family, and particularly
FGF-2, basic FGF. Many FGF isoforms affect cells in the
vascular wall. FGF use four cell surface receptors, FGFR-1
to FGFR-4.5 One of the effects of FGF-2 binding to its
Fig 2. Schema of possible events in the arteriogenic process. EC, Endothelial cell; SMC, smooth muscle cells; MCP-1,
monocyte chemoattractant protein-1; GM-CSF, granulocyte-macrophage colony-stimulating factor; PDGF, platelet-
derived growth factor; TNF-alfa, tumor necrosis factor-.
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receptor is stimulation of endothelial cells and smooth
muscle cell (SMC) proliferation. Cell proliferation is fol-
lowed by disruption of lamina elastica interna and migra-
tion of SMC to form a neointima. Remodeling of the vessel
is the final step that, in large part, occurs in the adventitial
layer. SMCs and fibroblasts are important during this
stage.6 The external elastic lamina and elastin in the adven-
titia and surrounding tissue are broken down by protelytic
enzymes, eg, MMP and plasmin. This provides space for
the growing vessel. At this stage the vessel’s old structure is
more or less taken apart. FGF-2 then stimulates fibroblast
maturity, and additional cell layers are added to the vessel
wall.
Many collateral vessels contribute to counteract the
increase in shear, but some vessels can enlarge more than 20
times. The newly formed collateral vessel is initially tortu-
ous, to compensate for still increased shear forces, but
eventually it becomes indistinguishable from a normal ar-
tery. It has then both a medial layer and normal reactivity.
EMBRYONAL DEVELOPMENT OF BLOOD
VESSELS: EQUIVALENT TO VESSEL GROWTH
IN THE ADULT?
There is reason to believe that the basic mechanisms of
angiogenesis and arteriogenesis are similar in the adult, in
normal states as well as in disease, as in vascular develop-
ment in the embryo and during the postnatal period. The
stages involved appear to be the same, perhaps with the
exception of vasculogenesis. This is the initial process dur-
ing vascular development of the major vessels and the heart,
when endothelial cells evolve from mesoderm-derived pro-
genitors in areas that lack blood vessels. These endothelial
cells then adhere to one another and form tubes and
networks. Development of leg arteries, however, occurs
later during gestation, and vasculogenesis is probably not a
major feature. Limb development starts around week 7
with formation of buds from the trunk. The processes
responsible for leg artery development and growth in these
buds are primarily angiogenesis and remodeling. Remodel-
ing has many similarities to arteriogenesis in the adult, and
is most prominent during the early postnatal period.
It has been suggested that primitive undifferentiated
vascular cells are present systemically also in the adult.7
Such endothelial precursor cells originate from bone mar-
row. These cells may be able to start a process similar to
vasculogenesis in the adult. Of interest, the promising
therapeutic angiogenesis concept of injecting bone marrow
cells into ischemic limbs to form new vessels can be re-
garded as “vasculogenesis.”8
Growth factors that control angiogenesis and vascular
remodeling are most likely also identical in the embryo and
the adult. As in the adult, the interplay between various
growth factors is complex throughout vascular develop-
ment and has not yet been completely explained. Various
VEGF family members and receptors also appear to have
specific functions during development. For example,
VEGF-B is most prominently expressed during tube forma-
tion. Angiogenic growth factors may nonetheless be more
important during certain stages than others. For example,
recruitment of mesodermal cells seems to be controlled
primarily by FGF-2, whereas differentiation of angioblasts
to endothelial cells and formation of primary networks are
largely regulated by VEGF. Angiopoetin and its receptor
Tie-2 are probably important, in addition to VEGF, for
vascular branching.9 However, it must be remembered that
optimal vessel development and growth require several
growth factors and timing of events.
Considering the similarities between embryonal and
adult vessel formation, much of the information gained by
studying embryonal vessel formation can be applied to
adult vessels and as mechanistic background for therapeutic
angiogenesis purposes. For example, conditions and pep-
tides involved in vascular branching during vascular devel-
opment can be used to stimulate development of new
arteries from atherosclerotic main branches.
IMPLICATIONS FOR PATHOPHYSIOLOGY
AND TREATMENT OF LIMB ISCHEMIA
Angiogenesis. The angiogenesis mechanisms de-
scribed are based on experimental data not focused on limb
ischemia. While not yet established in patients, it is proba-
ble that angiogenesis occurs in ischemic tissue in acute limb
ischemia. In animal models a burst of VEGF appears to be
released directly after ischemic induction in ischemic skel-
etal muscle. Upregulated transcription and production of
VEGF, VEGFR-2, and HIF- have also been observed.
Most VEGF comes from myocytes and macrophages, and
expression appears to be greater in oxidative muscles than
in glycolytic muscles. The increase in VEGF production
lasts at least 3 weeks and seems to be accompanied by
increased capillarity and increased uptake of bromode-
oxyuridine by endothelial cells in these animal models.
FGF-2 is also present in large amounts in ischemic tissue
directly after ischemic induction, but not after 1 week.10
The main producers of FGF-2 are inflammatory cells. An-
ecdotal data in patients with acute limb ischemia supports
these observations. VEGF and its receptors are also upregu-
lated after rather short periods of arterial occlusion in
healthy subjects. Little is known about expression of other
angiogenic proteins in acute limb ischemia.
Information on angiogenesis is even more limited in
chronic disease, because of lack of appropriate animal mod-
els. Patients with chronic ischemia are reported to have
higher systemic levels of FGF-2 compared with control
subjects. A probable source of this is inflamed skin rather
than ischemic muscle. VEGF levels do not seem to be
extensively elevated systemically or locally in the chronically
ischemic leg. There are, however, conflicting data regard-
ing this. In tissue samples obtained during reconstructive
vascular surgery, very low levels of VEGF are found in
muscle tissue at distal sites (Palmer-Kazen, unpublished
data), whereas high concentrations have been measured in
certain parts of amputated legs.11 In the study by Rissanen
et al,11 VEGF was co-localized with HIF- and macro-
phages in atrophic and regenerating muscle tissue. In-
creased levels of VEGF in that study correlated with
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VEGFR-2 upregulation. In the literature there is little
evidence that increased receptor expression compensates
for attenuated growth factor production. Presently there
appear to be few reports that show active angiogenesis in
chronic limb ischemia. This may be because of heteroge-
neous distribution of angiogenesis in the ischemic leg or
lack of methods to assess angiogenesis, or because this
process is not central in chronic disease.
Almost 50% of patients with limb ischemia have diabe-
tes. It has been suggested that increased risk for ischemia
and the relatively poor prognosis for patients with diabetes
compared with patients without diabetes may be due to
defective angiogenesis. This may appear contradictory,
considering diabetic retinopathy, a complication largely
caused by increased neovascularization and VEGF upregu-
lation. The evidence supporting impairment in diabetes
consists of a reduced number of capillaries compared with
control in biopsy specimens from patients with coronary
artery disease and low levels of vascular growth factors,
receptors, and messenger RNA around ischemic ulcers and
in ischemic muscle from animal models of diabetes.12 The
mechanism of such presumed impaired angiogenesis in
limb ischemia is probably complex and may be due to
disturbances in one of the steps in the angiogenesis process.
Smoking may also affect ability to form new blood
vessels. While not proved in patients with peripheral artery
disease, there is indirect evidence that the angiogenesis
process is negatively influenced by smoking. Healthy smok-
ers have decreased levels of VEGF systemically, and patients
with squamous cell carcinoma who smoke have lower mi-
crovessel density and VEGF concentration in the tumor
compared with matched nonsmokers. The substance in
cigarette smoke that exerts this effect is unknown. Of
interest, nicotine appears to have a dose-dependent effect,
stimulating endothelial cell proliferation in vitro at low
levels while being directly cytotoxic at higher concentra-
tions.13
Arteriogenesis. The arteriogenic mechanisms de-
scribed have, to a large extent, been elucidated in animal
models of acute limb ischemia. Large animal models devel-
oped to create gradually constricting stenosis in one coro-
nary artery have also been helpful. The location, timing,
and extent of growth factor, receptor, and enzyme produc-
tion have largely been demonstrated by Schaper et al in
Germany, using a combination of in vitro and in vivo
approaches. Overall, there is ample evidence that arterio-
genesis occurs and is essential for restoring perfusion in
animal models of limb ischemia.
There is little information, however, about arteriogen-
esis in patients. The presence of collateral vessels is obvious
to anyone that has seen angiograms, but not much is
known about the development of such angiographically
evident collateral vessels or their capacity to ease symptoms.
For example, the effect of exercise training programs in
patients with claudication seems to improve muscle metab-
olism and oxygen uptake rather than collateral vessel capa-
bility. There is a weak relationship between increased lower
limb blood flow and walking distance after exercise treat-
ment, indicating that the increased flow accounts for less
than 30% of the improvement.14 The main benefit of
exercise is less reliance on anaerobic metabolism and better
muscle energy.15
It is also unknown what risk factors affect collateral
vessel development in limb ischemia. We found that having
few profunda collateral vessels when the superficial femoral
artery was occluded was related to diabetes, short duration
of symptoms, and smoking in patients with claudication
(De Vivo S, unpublished data). Patients with diabetes and
coronary artery disease also have a reduced number of
collateral vessels compared with patients with coronary
artery disease without diabetes.16 As in animal models,
there does not seem to be upregulation of vascular growth
factors or extensive inflammation in the tissue surrounding
the developing collateral artery in patients with limb isch-
emia.
Pathophysiology. Arteriogenesis appears to be an im-
portant part of the pathophysiology of limb ischemia, con-
tinuing for a long time after onset of disease, whereas
angiogenesis may function mainly in acute situations. One
may speculate, however, that angiogenesis may occur in
certain parts of the leg with chronic disease that experience
abrupt inhibition of blood supply, as in even subclinical
acute thrombosis. Moreover, border zones between ne-
crotic metabolically inactive tissue may become ischemic
during increased demand, creating a milieu suitable for new
vessel formation.17 This explanation would also be benefi-
cial for synergetic effects of angiogenesis and arteriogenesis.
Reaching the absolute claudication distance may also stim-
ulate both processes.
Implications for treatment. Increased knowledge of
the effects of endogenous angiogenesis and arteriogenesis
in limb ischemia may facilitate optimization of exercise
therapy and pharmacologic treatment. With identification
of patients with a poor prognosis, active measures could be
started and selection to vascular surgical procedures would
be easier. To achieve such effects and to make therapeutic
angiogenesis more successful, research efforts focusing on
patients and the physiology of endogenous angiogenesis
and arteriogenesis are needed.
The TRAFFIC trial18 is the first randomized clinical
trial to show a positive effect of growth factor administra-
tion in patients with ischemic limbs. Recently bone marrow
mononuclear cells injected into muscle have also been
shown to stimulate angiogenesis in patients with chronic
ischemia in a small randomized trial.8 Other than these
examples, there are no studies proving the concept of
therapeutic angiogenesis. Considering the basic mecha-
nisms of angiogenesis and arteriogenesis described, at-
tempts to treat limb ischemia should probably be directed
toward arteriogenesis. The ideal therapeutic concept would
probably involve efforts to make vessels grow further be-
yond harmonization of shear forces so that collateral capac-
ity could sufficiently ameliorate all symptoms. Treatment to
keep collateral vessels “active” as long as possible by pro-
longing the proliferation and remodeling phases of arterio-
genesis may be a way to achieve this. This concept is being
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tried in clinical trials presently starting up using MCP-1 and
GM-CSF supplementation. Another possibility is combina-
tion treatment, eg, FGF-2 and platelet-derived growth
factor-BB, which creates long- lasting functional collateral
vessels in animal models of limb ischemia.19
SUMMARY
When the concept of therapeutic angiogenesis was
launched, the complexity of angiogenesis and arteriogen-
esis were underestimated. Today most researchers believe
that simply adding vascular growth factors to an ischemic
area is not sufficient for effective therapeutic angiogenesis.
While the mechanisms involved in these processes are start-
ing to be revealed, their effect on the pathophysiology of
limb ischemia needs to be further clarified. Such informa-
tion will make future treatment efforts more likely to suc-
ceed.
I thank Johan Runow for help with the illustrations.
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